Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rh... (ed to join the company in this exciting ...)

Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island

Date:10/21/2008

ed to join the company in this exciting celebration today."

"Through the support of our RIEDC financing tools, we were able to assist Neurotech, a very promising Rhode Island biotechnology company, grow and expand their operations in our state. Strengthening Rhode Island's life sciences sector and creating more high-wage jobs for Rhode Islanders is a very high priority of our Economic Growth Plan," said Saul Kaplan, executive director, Rhode Island Economic Development Corporation. "Today's announcement is an excellent example of how the public and private sectors can work together to help great companies grow and expand here. We are proud of Neurotech's success and recognize the importance of assisting promising biotechnology companies as their therapies move from the lab to commercialization."

About Neurotech's Clinical Programs:

Phase 2/3 Studies in Retinitis Pigmentosa (RP)

Neurotech is conducting two Phase 2/3 trials of NT-501 for the treatment of visual loss associated with RP-one consisting of patients with earlier stage disease (60 patients) and the second consisting of patients with later stage disease (60 patients). Both trials are randomized, multi-centered, double-masked, sham-controlled dose ranging studies. Each patient receives either a high or low dose NT-501 implant in one eye and a sham treatment in the fellow eye. The primary efficacy endpoint is visual field sensitivity for the early-stage RP study and best corrected visual acuity for the late-stage RP study.

Phase 2 Study - Dry Age-related Macular Degeneration (Dry AMD)

This randomized, multi-centered, double-masked, sham-controlled study is evaluating NT-501 in 48 subjects with an advanced stage of dry AMD called geographic atrophy. Each subject receives either a high or low dose NT-501 implant or a sham treatment in one eye only. Best corrected visual acuity is the primary efficacy endpoint of this study.

About the Diseases

Retinitis Pigm
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. ORIMtec Releases Industry's First Intraoperative Monitoring Reference Guide for Neurotechnologists
2. New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems
3. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
4. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
5. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
6. Laureate Announces Manufacturing Agreement with Tolerx
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
9. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
10. RSCI Announces Two Additions to Its Science Advisory Board, Calling for More Stem Cell Research on Diabetes
11. ADVENTRX Announces Restructuring and Cost Reduction Initiatives

Post Your Comments:

Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rh...(ed to join the company in this exciting ...)